JWH-217

JWH-217_structure.png

JWH-217 is a synthetic cannabinoid from the naphthoylindole family, which acts as a potent agonist of the cannabinoid receptors. It was first synthesized by John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.

Chemical Structure and Properties

JWH-217 is chemically classified as a naphthoylindole, which is a subclass of synthetic cannabinoids. Its chemical structure consists of a naphthalene group attached to an indole core, with a fluoropentyl chain at the nitrogen atom of the indole. The presence of the fluorine atom in the pentyl chain is a distinguishing feature of JWH-217 compared to other synthetic cannabinoids.

The molecular formula of JWH-217 is C₂₅H₂₄FNO, and it has a molecular weight of 373.47 g/mol. The compound is typically a white to off-white powder and is soluble in organic solvents such as ethanol and dimethyl sulfoxide (DMSO).

Pharmacology

JWH-217 acts as a full agonist at both the CB₁ and CB₂ cannabinoid receptors, with a higher affinity for the CB₂ receptor. This receptor selectivity is of interest in research as it may lead to the development of compounds with therapeutic potential that have reduced psychoactive effects compared to traditional cannabinoids like THC.

The binding affinity of JWH-217 for the CB₁ receptor is reported to be in the low nanomolar range, indicating a high potency. This high affinity and potency make JWH-217 a useful tool in cannabinoid receptor research, although its use is limited to laboratory settings due to its potential for abuse and lack of safety data in humans.

Legal Status

The legal status of JWH-217 varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other synthetic cannabinoids that have been associated with adverse health effects and abuse potential. Researchers must obtain appropriate licenses to work with JWH-217 in countries where it is regulated.

Research and Applications

JWH-217 is primarily used in scientific research to study the effects of cannabinoid receptor activation and to explore the potential therapeutic applications of cannabinoid receptor agonists. It has been used in studies investigating the role of the endocannabinoid system in pain modulation, inflammation, and neuroprotection.

Safety and Toxicology

There is limited information available on the safety and toxicology of JWH-217 in humans. As with other synthetic cannabinoids, there is a potential for adverse effects, including tachycardia, hypertension, anxiety, and hallucinations. Due to these risks, JWH-217 is not approved for human consumption and should only be handled by trained professionals in a controlled laboratory environment.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman
• JWH-018
• Endocannabinoid system